OPTIMIERTE FAKTOR-VIII-GENE

Patent europeic · EP3411478 · En vigur

Inscripziun en il register

Numer da publicaziun
EP3411478
Numer da la dumonda
EP17705236
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
31-01-2017
Publitgà
12-12-2018
Concedì
08-06-2022
La protecziun finescha il pli tard
30-01-2037
Proxima taxa annuala scadenta
31-01-2027
Classas IPC
C12N 9/64 (2006.01)
Prioritad
US 201662289696 P 01.02.2016
US 201662409739 P 18.10.2016
Dumonda PCT
PCT/US2017/015879 31.01.2017
Publicaziun PCT
WO2017/136358 10.08.2017
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-02-2026

    Midada

    Published in Swissreg on 01.02.2026

  2. 01-02-2025

    Midada

    Published in Swissreg on 01.02.2025

  3. 01-02-2024

    Midada

    Published in Swissreg on 01.02.2024

  4. 19-04-2023

    Midada

    Published in Swissreg on 19.04.2023

  5. 01-02-2023

    Midada

    Published in Swissreg on 01.02.2023

  6. 08-06-2022

    Concedì

    Published in Swissreg on 08.06.2022

Partidas

Possessur

Bioverativ Therapeutics Inc.

225 Second Avenue, Waltham, MA 02451, US

Inventur

LIU, Tongyao

Lexington, Massachusetts 02421, US

TAN, Siyuan

Lexington, Massachusetts 02421, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.